Opioid–D3R Agonist Combination to Maintain Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid treatments for chronic pain lose efficacy over time, leading to drug tolerance and increased risk of addiction, with existing mechanisms failing to address these issues effectively.
Innovation Solution
Administering a combination of opioids and dopamine type 3 receptor (D3R) agonists to maintain opioid efficacy, reduce tolerance, and lower the risk of addiction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids are administered for chronic pain treatment, then pain relief is achieved, but opioid tolerance develops and efficacy is lost over time
Solution Approach 1:
The patent introduces a dopamine D3 receptor agonist as an intermediary substance that modulates the opioid system. This agonist acts as a mediator to prevent opioid tolerance and maintain efficacy without directly providing analgesia itself, thereby extending the duration of opioid action.
Solution Approach 2:
The patent changes the pharmacological parameters by combining opioids with dopamine D3 receptor agonists, altering the receptor activation profile. This parameter change prevents the development of tolerance and maintains opioid efficacy over extended periods.
2Reliability
If opioid doses are increased to maintain efficacy, then pain relief is maintained, but risk of addiction and dependence increases
Solution Approach 1:
The dopamine D3 receptor agonist serves as an intermediary that allows maintenance of opioid efficacy at lower doses. By modulating the opioid system through this intermediary, the patent reduces the need for high opioid doses, thereby decreasing addiction and dependence risks.
Solution Approach 2:
The patent extracts the tolerance-preventing function from the opioid itself and assigns it to the dopamine D3 receptor agonist. This separation allows the opioid to focus on pain relief at lower doses while the agonist handles the tolerance prevention, reducing harmful effects.
3Duration of action of stationary object
If long-term opioid treatment is used, then chronic pain is managed, but drug tolerance develops reducing treatment effectiveness
Solution Approach 1:
The patent ensures continuous useful action by combining opioids with dopamine D3 receptor agonists. This combination maintains treatment effectiveness throughout long-term use, preventing the interruption of pain relief that occurs when tolerance develops to opioid monotherapy.
Solution Approach 2:
The dopamine D3 receptor agonist performs preliminary action by preventing tolerance development before it occurs. This proactive approach maintains opioid sensitivity and treatment effectiveness throughout the duration of long-term therapy.
Data Source
AI summary
The present invention provides methods for treating and/or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.